TrkB-target galectin-1 impairs immune activation and radiation responses in neuroblastoma: Implications for tumour therapy
Galectin-1 (Gal-1) has been described to promote tumour growth by inducing angiogenesis
and to contribute to the tumour immune escape. We had previously identified up-regulation
of Gal-1 in preclinical models of aggressive neuroblastoma (NB), the most common
extracranial tumour of childhood. While Gal-1 did not confer a survival advantage in the
absence of exogenous stressors, Gal-1 contributed to enhanced cell migratory and invasive
properties. Here, we review these findings and extend them by analyzing Gal-1 mediated …
and to contribute to the tumour immune escape. We had previously identified up-regulation
of Gal-1 in preclinical models of aggressive neuroblastoma (NB), the most common
extracranial tumour of childhood. While Gal-1 did not confer a survival advantage in the
absence of exogenous stressors, Gal-1 contributed to enhanced cell migratory and invasive
properties. Here, we review these findings and extend them by analyzing Gal-1 mediated …
Galectin-1 (Gal-1) has been described to promote tumour growth by inducing angiogenesis and to contribute to the tumour immune escape. We had previously identified up-regulation of Gal-1 in preclinical models of aggressive neuroblastoma (NB), the most common extracranial tumour of childhood. While Gal-1 did not confer a survival advantage in the absence of exogenous stressors, Gal-1 contributed to enhanced cell migratory and invasive properties. Here, we review these findings and extend them by analyzing Gal-1 mediated effects on immune cell regulation and radiation resistance. In line with previous results, cell autonomous effects as well as paracrine functions contribute to Gal-1 mediated pro-tumourigenic functions. Interfering with Gal-1 functions in vivo will add to a better understanding of the role of the Gal-1 axis in the complex tumour-host interaction during immune-, chemo- and radiotherapy of neuroblastoma.
MDPI